Twitxy Saved

Evald Høj Christiansen

@h_evald

Professor, Cardiologist, trialist, PhD, father, husbond, son, keen on getting the best treatment for patients now and in the future, H index of 78
Aarhus Joined October 2019
268 Following 644 Followers 231 Posts

Latest posts 5

Evald Høj Christiansen @h_evald
How can the IR for recurrent MI of 0,2% in the ticagrelor arm versus 0,4% in the prasugrel arm be in favor of prasugrel? The adjHR is presented as 0,65 in favor of prasugrel??
Davide Capodanno Verified account @DFCapodanno Nov 22, 2025
A shift from ticagrelor to prasugrel occurred in Denmark following the findings of the ISAR-REACT 5 trial and the updated ESC guideline recommendation favoring prasugrel. In 2019, more than 99% of patients received ticagrelor; by 2022, 89% received prasugrel.

This study is truly exceptional in its scope: among 10,984 patients with myocardial infarction undergoing PCI, prasugrel was associated with lower rates of MACE and recurrent myocardial infarction after statistical adjustment, with similar bleeding rates compared with ticagrelor. These results were replicated in a propensity score–matched cohort, in patients aged ≥75 years, and in those with non-STEMI.

Considering the TUXEDO-2 data presented at #AHA25 and soon to be published, and with the inevitable meta-analysis that will strengthen the case for prasugrel, this nationwide study adds further evidence that the two "more potent P2Y12 inhibitors" are, after all, not as equivalent as often assumed.

eurointervention.pcronline.com/article/impact…
View quoted post on X